Calcineurin as a possible new target for treatment of Parkinson's disease
- 30 September 1994
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 43 (3) , 132-134
- https://doi.org/10.1016/0306-9877(94)90136-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Signal integration at the level of protein kinases, protein phosphatases and their substratesTrends in Biochemical Sciences, 1992
- High brain densities of the immunophilin FKBP colocalized with calcineurinNature, 1992
- Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activityBiochemistry, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson's DiseaseScience, 1990
- Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slicesNature, 1990
- Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1Nature, 1984
- DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brainJournal of Neuroscience, 1984
- A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regionsNature, 1983